Roche signs antibody-drug conjugate deal with Hansoh worth up to $15 billion
Roche pays $400 million up front, and Hansoh will contribute two preclinical ADCs and develop others against targets Roche proposes.
Roche pays $400 million up front, and Hansoh will contribute two preclinical ADCs and develop others against targets Roche proposes.